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Abstract
Background: Worldwide, alcohol abuse is a burgeoning problem. Abstinence is key to allow recovery of physical
and mental health as well as quality of life, but treatment for alcohol dependence is associated with high relapse
rates. Preliminary data have suggested that a combined repeated ketamine and psychological therapy programme
may be effective in reducing relapse in severe alcohol use disorder. This non-commercial proof-of-concept trial is
aimed at making a preliminary assessment of the effectiveness of this combined treatment in this patient group.
Methods/design: This is a phase II, randomised, double-blind, placebo-controlled, parallel-group clinical trial taking place
in two sites in the UK: the South West of England and London. Ninety-six recently detoxified alcoholics, with comorbid
depressive symptoms, will be randomised to one of four treatment arms. Patients will receive either three sessions of
ketamine (0.8 mg/kg administered intravenously (IV) over 40 minutes) or placebo (50 ml saline 0.9% IV over 40 minutes)
plus either seven sessions of manualised psychological therapy or an alcohol education control. Patients will be assessed
at 3 and 6 months on a range of psychological and biological variables. The primary endpoints are (1) relapse rates at
6 months and (2) percentage days abstinent at 6 months. Secondary endpoints include 3 and 6 month percentage days
abstinence, tolerability (indicated by dropout), adverse events, depressive symptoms, craving and quality of life.
Discussion: This study will provide important information on a new combined psychological and pharmacological
intervention aimed at reducing relapse rates in alcoholics. The findings would have broad application given the
worldwide prevalence of alcoholism and its associated medical, psychological and social problems.
Trial registration: ClinicalTrials.gov, NCT02649231. Registered on 5 January 2016.
Keywords: Alcoholism, Ketamine, Relapse, Depression
Background
Alcohol misuse globally accounts for roughly 4% of all
deaths and 5% of the burden of disease [1]. In the UK
alone, nearly 9% of men and 4% of women today meet
criteria for alcohol dependence — in all approximately
3.9 million British adults [2]. In the UK, 22,000 people
die annually because of alcohol misuse, which can pro-
duce severe and enduring physical and neurological
problems. Costs to the National Health Service (NHS)
from alcohol abuse are estimated at £2.7 billion annually
[1]. Abstinence is pivotal in order to tackle problems
associated with alcohol dependence, but alcohol depend-
ence is associated with high relapse rates.
Pilot work conducted in the 1980s found unprecedented
reductions in relapse rates in alcoholism following keta-
mine treatment. Three weekly doses (2.5 mg/kg bolus IM)
of ketamine were given alongside sessions of psychother-
apy before and after the administration of the drug to 111
recently detoxified alcohol-dependent patients. One year
later, 66% of the patients in this group were still abstinent.
In comparison, out of a control group of 100 similar
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recently detoxified alcohol-dependent patients, 24% were
abstinent after 1 year [3]. A 40% reduction in relapse rate
is much greater than anything previously observed with
any other relapse prevention method in alcohol depend-
ence. However, in the latter study patients could freely
choose which treatment condition they wanted to experi-
ence, and so the experiment was neither blinded nor a
randomised controlled trial. Nevertheless, these prelimin-
ary findings have been supported by case studies of the
successful use of ketamine, alongside transpersonal ther-
apy, in the treatment of alcoholism, where 15 patients had
70% abstinence rates at 1 year [4].
At the time of the pilot work in alcohol dependence in
Russia, any potential biological mechanism was unclear.
However, the remarkable recent success of isolated doses
of ketamine in the treatment of depression [5, 6] suggests
that a similar biological mechanism could be in operation
in this observed reduction of relapse in alcoholism follow-
ing ketamine. The proposed biological mechanism behind
the anti-depressant effects of ketamine is increased synap-
togenesis, and recent empirical evidence suggests that
blocking synaptogenesis also blocks ketamine-induced re-
ductions in alcohol consumption [7]. We are proposing
that ketamine may reduce relapse in alcoholism via stimu-
lating the growth of neurons and synapses and enhancing
the uptake of psychological therapy.
Recent theoretical accounts have proposed a role for
impaired neurogenesis and synaptogenesis in addiction
[8, 9]. These accounts are supported by pre-clinical studies
that suggest that these processes are blocked following ad-
ministration of addictive substances, in particular alcohol
(see, e.g. [10–15]). Changes in potential indices of neuro-
genesis, such as serum brain-derived neurotrophic factor
(BDNF), are observed in alcoholics [16], with levels in-
creasing with their sobriety [17]. Reducing the numbers of
newborn neurons and synapses has been suggested as a
means of making the addicted brain less able to learn about
non-drug rewards and unable to project into the future [8].
Psychosocial therapies are currently the mainstays of
treatment for alcohol dependence but are of limited
effectiveness, which may partly be because they depend
on the brain’s capacity for neuroplastic change [18].
Psychological therapies in alcoholism are also less effect-
ive in individuals with cognitive impairment [19]. Under-
going psychological therapy, which involves learning and
thinking in different ways, during the period of neuro-
genesis and synaptogenesis after an acute dose of keta-
mine [20] may facilitate its uptake, as the brain is thus
primed to make new connections and learn new infor-
mation. Increased synaptogenesis has been linked with
improved memory (see, e.g. [21, 22]). Therefore, keta-
mine may enhance the uptake of psychological therapy
on the day following an acute dose by making the brain
more receptive to new learning.
In order to examine whether enhancing the uptake of
therapy is the mechanism by which ketamine is effective
in alcoholism, we have included a ketamine with ‘no ther-
apy’ (i.e. alcohol education) arm in the trial. These data will
have considerable implications not only for alcohol depend-
ence, but also depression, since patients with comorbid de-
pressive symptoms are being recruited for this trial. Positive
findings may suggest that a similar psychotherapy plus keta-
mine approach may enhance the effectiveness of ketamine
treatment in patients with depressive symptoms.
The research question is whether ketamine can reduce
relapse in alcohol dependence. To address this question, we
are carrying out a phase II, multi-site, randomised, double-
blind, placebo-controlled, parallel-group clinical trial inves-
tigating the impact of a novel brief pharmacological and
psychological intervention aimed at reducing relapse rates
in recently detoxified alcohol-dependent individuals with
depressive symptoms. We predict that ketamine compared
to placebo will reduce relapse at 6 months. Additionally we
hypothesise that ketamine will have a synergistic effect with
psychological therapy, reducing relapse rates at 6 months
(increasing the percentage of days abstinent) as compared
to ketamine plus alcohol education control.
Methods/design
Overview of study design
This study is a non-commercial, randomised, double-
blind, parallel-group clinical trial with four treatment
arms: (1) ketamine and psychological therapy, (2) keta-
mine and alcohol education, (3) saline and psychological
therapy and (4) saline and alcohol education. Eligible
participants will be recruited from two study sites in the
UK, London and the South West of England.
Eligibility criteria
All prospective patients will be assessed to determine
eligibility by the study team according to the inclusion
and exclusion criteria outlined below. Every prospective
patient will be informed about the trial design and
protocol by the study team and will be encouraged to
discuss suitability with a non-study member.
Inclusion criteria
The inclusion criteria are as follows:
 18 to 60 years old.
 Meet either (1) Diagnostic and Statistical Manual of
Mental Disorders (DSM)-5 criteria for severe
alcohol use disorder or (2) DSM-IV criteria for
severe alcohol dependence within the last 12 months.
 Currently abstinent from alcohol (breathalyser blood
alcohol concentration (BAC) level 0.00) and negative
urine drug screen (participants testing positive for
tetrahydrocannabinol (THC) who do not have a
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history or current cannabis dependency may be
included). THC dependency will be assessed by
general practitioner (GP) correspondence as well
as self-disclosure of seeking help for a cannabis
dependency. THC use will be assessed using urine
drug tests at each trial visit as well as during drug
histories administered at the screening visit and at
visits 8, 9 and 10.
 Minimum of mild depression (>14 on Beck
Depression Inventory-II).
 Capacity to give informed consent as defined by
Good Clinical Practice (GCP) guidelines.
 Willing and able to wear Secure Continuous Remote
Alcohol Monitor (SCRAM-X) bracelet for 6 months.
 Females of childbearing potential and males must be
willing to use an effective method of contraception
(hormonal or barrier method of birth control; true
abstinence) from the time consent is signed until
6 weeks after treatment discontinuation and inform
the trial if pregnancy occurs.
 Females of childbearing potential must have a
negative pregnancy test within 7 days prior to being
registered for trial treatment and on the day of first
treatment.
Exclusion criteria
The exclusion criteria are as follows:
 Currently taking any other relapse prevention
medication or anti-depressants
 Uncontrolled hypertension (systolic 140 mm Hg or
greater and diastolic 90 mm Hg or greater)
 Body mass index (BMI) outside normal limits (<16
and >35)
 History of psychosis, or psychosis in a first-degree
relative, as identified by DSM-5 or DSM-IV Struc-
tured Clinical Interview (SCID); co-morbid psychi-
atric diagnosis excluding depression, identified via
self-report or notified by their medical professional
 Previous or current diagnosis of substance
dependence/severe substance misuse disorder
 History of neuropsychological difficulties
 One or more confirmed seizures
 Currently taking daily prescribed medication
contraindicated in the Summary of Product
Characteristics (SPC)
 Liver function tests greater than three times normal
levels
 Where there are special warnings or precautions for
use according to the SPC where the risk benefit
ratio is not in favour of giving ketamine with
assessment made by physical examination by
medically qualified trial personnel, self-report or
inspection of the medical notes:
◦ Acute intermittent porphyria
◦ Dehydration or hypovolaemia
◦ Hyperthyroidism, or patients receiving thyroid
replacement
◦ Pulmonary or upper respiratory tract infection
◦ Severe coronary artery disease, cerebrovascular
accident or cerebral trauma
◦ Diabetes
◦ Known glaucoma or globe injuries
◦ Cirrhosis
◦ Epilepsy
◦ Neurological condition/brain damage
◦ Intracranial mass lesions, presence of head injury
or hydrocephalus
 Suicidal ideation
 Not willing to use effective contraception or
(females) take pregnancy test
 Allergic reaction to ketamine
 More than ten previous detoxifications from alcohol
 Pregnant or breastfeeding
 Allergies to excipients of the investigational
medicinal product (IMP) or placebo
 Use of another IMP that is likely to interfere with
the study medication within 3 months of study
enrolment
Randomisation, blinding and unblinding
Simple randomisation will be used to allocate patients
using a 1:1:1:1 ratio for the four respective study arms.
Randomisation will be performed by a specialist com-
pany (www.sealedenvelope.com) who will hold a ran-
domisation list and provide 24/7 Internet access for
unblinding services. Early dropouts (during screening
and up until randomisation) will be replaced. Once pa-
tients have been randomised, they will not be replaced
regardless of compliance or dropout status and will be
analysed as part of the intention-to-treat analysis. Ran-
domisation will be performed by delegated medical staff
who are satisfied with patient eligibility to participate.
Two emails will be sent on randomisation, one to dele-
gated staff preparing the IMP detailing whether the IMP
or placebo should be provided for infusion, and another
to the psychologists determining whether therapy or
education should be undertaken.
Upon randomisation, patients will be provided with a
study-specific patient card which will have details
regarding the study title, IMP details, patient ID and
contact details of the out-of-hours contact in cases of
emergency. The study code should only be broken for
valid medical or safety reasons, e.g. in the case of a
severe adverse event where it is necessary for the
investigator or treating health care professional to know
which treatment the patient is receiving before the
patient can be treated. Subject always to clinical need,
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where possible, members of the research team will
remain blinded. The code breaks for the trial are held at
www.sealedenvelope.com. Authorised members of the
research team will have administrative rights to the
unblinding system, and a nominated individual will be
available 24 hours a day.
Trial structure
Patients involved in this trial will go through ten study
visits, an overview of which can be seen in Fig. 1. Specific
details about study activities that will be undertaken at
each visit can be found in the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
checklist (Additional file 1) and in Fig. 2.
Pre-screening assessment
Patients identified as wanting to take part in this study
will receive a telephone assessment by a member of the
research team to discuss the trial and confirm initial
eligibility using the inclusion and exclusion criteria out-
lined above. Where applicable, a screening visit will be
booked for those who pass the initial eligibility and still
express interest in participating.
Screening visit
Formal screening will take place at one of the two study
sites. Consent will be taken from the patient prior to any
assessments at this visit. Following this, a variety of
physical and psychological assessments will be under-
taken, details of which can be found in the SPIRIT
checklist, in order to further determine eligibility. Those
still meeting criteria for inclusion at the end of this visit
will be fitted with the SCRAM-X bracelet, and a date for
the baseline visit will be arranged within 14 days of the
screening date. In between study visits a delegated an-
aesthetist will determine whether patients are potentially
eligible to be randomised into the trial.
Intervention
Baseline assessments
At the start of the baseline visit, certain assessments will be
undertaken to ensure eligibility is still reliable. Patient vital
signs will be checked, and a concomitant medication review
will be undertaken, along with a breathalyser reading and
urine drug screen and, where applicable, a pregnancy test.
The SCRAM-X bracelet will be checked. If the patient is
happy and is eligible, the anaesthetist will randomise the
patient into the trial, and baseline data will be collected
from a variety of psychological assessments, details of
Fig. 1 KARE trial design. Step 1: Participants are initially identified and go through pre-screening. Step 2: If eligible, participants are invited for a
screening visit to further determine eligibility. Step 3: If eligible, participants are randomised into one of four treatment conditions: (1) ketamine +
relapse prevention therapy, (2) ketamine + alcohol education, (3) placebo + relapse prevention therapy, (4) placebo + alcohol education. Treatment
runs over 7 sessions (1 therapy/education per session, ketamine/placebo is administered in 3 sessions). Step 4: Participants are followed up at
12 weeks. Step 5: Participants are followed up at 24 weeks
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Fig. 2 (See legend on next page.)
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which can be found in the SPIRIT checklist. A session of ei-
ther relapse prevention-based psychological therapy or an
alcohol education session will then be administered to the
patient depending on treatment allocation. Subsequently,
an infusion of either the IMP or placebo will be adminis-
tered. Further details about all four treatment allocations
are detailed below.
Relapse prevention-based psychological therapy
Across the initial baseline and subsequent six study visits,
half of the patients will receive psychological therapy. This is
a manualised therapy developed with alcohol specialist clin-
ical psychologists. This manual is not available in published
form. The aim of the seven sessions is to help to develop an
enjoyable and meaningful life without alcohol. It focuses
around two broad themes. The first theme relates to relapse
prevention, i.e. skills and strategies to reduce the likelihood
of relapse and maintain abstinence. The second theme
focuses on promoting well-being and deals with issues
such as purpose, meaning and life enjoyment, along with
skills of coping with life’s day-to-day problems and
stressors. Each session is designed to last one hour and
contains one topic related to relapse prevention and
another to promoting well-being. In between these two
main themes a different relaxation or mindfulness exercise
is introduced.
Alcohol education control
Half of the patients in this trial will receive seven sessions
of alcohol education, educating patients about the risks of
alcohol use and the effects of alcohol on the body. The
focus will be on topics including the driving forces of
addiction, the biological effects of alcohol, the way that
drugs interact with the brain, alcohol’s relationship with
other illnesses and ways to generally improve healthful
living. The alcohol education sessions will have no psycho-
logical components relating to personal relapse prevention
strategies or the promotion of personal well-being. Each
session has been designed to last one hour to be compar-
able to the psychological therapy sessions. These educa-
tion sessions should equate the amount of personal
interaction each patient has between the two conditions
(therapy and education), meaning interpersonal interaction
should not be responsible for any differences on the
research outcomes between these conditions.
IMP/saline placebo
Patients will receive three weekly intravenous infusions of
ketamine (Ketalar®), 0.8 mg/kg made up to 50 ml with
saline over 40 minutes, or three weekly infusions of
placebo, 0.9% saline over 40 minutes. The ketamine/pla-
cebo will be prepared in a blinded fashion by pharmacy or
delegated unblinded site staff and will be administered by
the research anaesthetist at the clinical research facility
who will remain blinded.
Subsequent study visits
Over the course of the trial, three visits will fall the day
after the preceding infusion visits (visits 3, 5 and 7).
These visits will importantly involve a session of relapse
prevention-based therapy or alcohol education. Visit 8
delivers the last psychological therapy or alcohol educa-
tion session in this trial. Visits 4 and 6 will be the two
other visits in which there is an infusion of ketamine or
placebo (as well as the baseline visit). Visits 9 and 10 are
the corresponding 3- and 6-month follow-up visits. The
SPIRIT checklist contains a complete list of all assess-
ments that will be conducted at each study visit.
Adverse event reporting
All adverse events will be recorded in the medical records
and case report form (CRF) only following consent. If an
investigator suspects that the patient’s disease has pro-
gressed faster due to the administration of the IMP, then
he/she will record and report this as an unexpected ad-
verse event. However, adverse events that are known to
the IMP when used in its licenced indication will only be
recorded in the medical notes, while serious adverse
events will be recorded in the CRF and serious adverse
events log. Clinically significant abnormalities in the re-
sults of objective tests (e.g. liver function, biochemistry)
will also be recorded as adverse events. If the results are
not expected as part of disease or IMP, they will also be re-
corded as unexpected. All adverse events will be recorded
until 6 months post-treatment. All serious adverse events
(See figure on previous page.)
Fig. 2 KARE trial SPIRIT checklist. This checklist contains all trial-specific assessments that will be run on each study visit. An ‘X’ denotes that this
assessment will be run. * Physical examination: cardiovascular, respiratory, gastrointestinal and neurological assessment to a level of detail that
would be expected for a patient due to receive anesthesia. ** Vital Signs: Resting pulse, pulse oximetry and blood pressure for safety monitoring.
Vital signs will also be continuously monitored throughout the infusion until the participant has recovered. Xa Bloods: Full Blood Count (haemoglobin,
white cell count, platelets, mean red cell volume); Liver Function Tests (Bilirubin, Alanine aminotransferase, Asparate aminotransferase, Total Protein,
Alkaline phosphatase, Albumin, Globulin, gamma-glutamyl transpeptidase), Biochemistry (urea, sodium, potassium, glucose, calcium, thyroid stimulating
hormone). Xb Bloods: Liver Function Tests (same as above); Brain-derived neurotrophic factor; ketamine. Xc Urine drug screen panel (methamphetamine,
cocaine, tetrahydrocannabinol, benzodiazepines, tricyclic antidepressants, barbiturates, phencyclidine, amphetamines, morphine, methadone) including
ketamine. Xd Urine drug screen panel (same as above) excluding ketamine
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will be reported to the sponsor from IMP administration
up to 30 days after last IMP administration.
Recruitment and timeline
Recruitment of the 96 patients across the two study sites
in England commenced in July 2016 and is expected to
last 2 years. Our justification of this sample size is as
follows: with n = 24 people in each drug arm we will be
able to estimate a decrease in the relapse rate from 50%
in patients given placebo to 25% (90% confidence inter-
val: 3–47%) in patients given ketamine.
A decrease of 25% in relapse would be clinically import-
ant and lower than that observed in the preliminary work
([3]: 42%); it would clearly suggest that further investiga-
tion is warranted. Our confidence intervals are relatively
broad, as this is a proof-of-concept study, and we wish to
minimise the numbers of subjects involved.
Patients will be primarily recruited from Participant Iden-
tification Centres (PICs). These centres will be the sub-
stance misuse and addiction psychiatry services in Central,
North West and South London as well as Devon, Dorset,
Wiltshire, Somerset and Bristol. These centres will refer po-
tential patients to the research team. If interested, PICs will
provide the patient with a Research Ethics Committee
(REC)-approved letter of invitation that contains details for
the patient to contact the study team directly. The research
team will then ensure that a copy of the Participant Infor-
mation Sheet (PIS) is made available to the patient prior to
any screening assessments. All patients will be included at
both follow-up periods of 3 and 6 months. The actual
timeline may be slightly different depending on patient
eligibility.
A study website will also be set up to accompany the
study, where patients can register their interest and
the trial will be publicised through forums and social
networking, relevant charities such as Foundation 66
and Alcohol Concern, newspaper, radio and TV, in
advice centres and via word of mouth and face-to-face
contact.
Database management
Anonymised trial data will be stored in a bespoke elec-
tronic CRF hosted on sealedenvelope.com, prepared using
their ‘Red Pill’ service. Trial-specific documents held by
researchers will be stored securely with access restricted
and limited to nominated research staff and in accordance
with the Data Protection Act 1998, University College
London (UCL) Information Security Policy and Trust In-
formation Governance Policy. Electronic and question-
naire source data will be stored in a password-protected
Microsoft Access database from where summary data will
be transcribed into the eCRF. The Red Pill database will
keep a record of all changes to and access of the database.
Definition of endpoints and outcome measures
Primary outcomes
The primary outcomes are the following:
 Relapse rates at 6 months
 Percentage days abstinent at 6 months
Secondary outcomes
Secondary outcomes are as follows:
 Number of days of continuous abstinence at
3 months
 Percentage days abstinent at 3 months
 State mood
 Depression
 Anxiety
 Psychotic symptoms
 Cigarette smoking
 Craving
 Quality of life
 Episodic memory
 Delay discounting
 Response inhibition
 Working memory
 Hippocampal functioning
 Adverse effects
For the purposes of this trial, relapse is defined as 5 drinks
(8.1 units of alcohol) or more in men and 4 drinks or more
(6.5 units of alcohol) in women on a single occasion.
Statistical methods
Primary outcome analysis
All analyses will be performed by a statistician blinded to
the treatment allocations and will be performed using
Stata v.13. The proportion of relapsed patients at the 6-
month follow-up will be reported as a percentage for each
arm, as well as for the ketamine arms combined and the
psychotherapy arms combined. The proportion of re-
lapsed participants at the 6-month follow-up will be
expressed as a relative risk with a 95% confidence interval
for the following comparisons: (1) all ketamine patients
versus all non-ketamine patients; (2) ketamine and
psychotherapy patients versus ketamine and education
patients; and (3) ketamine and psychotherapy patients ver-
sus placebo and education patients. These analyses are
purely exploratory and should be viewed with caution
both in light of lack of power and multiple testing. Per-
centage of days abstinent at the 6-month follow-up will be
reported descriptively in the same way by arm and com-
bination of arms; additionally between-group mean differ-
ence and 95% confidence intervals will be reported for the
comparisons set out above; again, these analyses should be
regarded as exploratory. The primary analysis will be an
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intention-to-treat (ITT) complete case analysis including
all randomised participants. A secondary analysis will be
conducted including only those patients deemed to have
completed to a sufficient degree their allocated interven-
tions, that is, a per protocol analysis.
Secondary outcome analysis
There are 15 secondary outcomes; all of these outcomes
will be reported descriptively on an ITT complete case
basis. Additionally, the between-group differences and
95% confidence intervals will be reported on an explora-
tory basis for the primary comparison (all ketamine
patients versus all non-ketamine patients). Also, as a feasi-
bility outcome, attrition will be reported as a proportion
(with 95% confidence interval) overall and by arm.
Sensitivity and other planned analyses
All patients will be in a state of detoxification at recruit-
ment; hence, in the event of loss of follow-up, it is not
appropriate to make an assumption that the patient had
or had not relapsed at 6 months. To address the issue of
missing data due to loss to follow-up, a sensitivity analysis
will be performed using multiple imputation methods,
and for relapse a 6-month follow-up only, making the
assumption that all missing data were missing at random.
Termination criteria
The end of the trial will be the last follow-up visit of the pa-
tient at 24 weeks post-baseline. All patients have the right
to withdraw at any time. In addition the Chief Investigator
(CI) may discontinue a patient from the study at any time it
is considered necessary for any reason including:
 Ineligibility (either during the study or retrospective)
 Significant protocol deviation
 Significant non-compliance with treatment or study
requirements
 An adverse event which requires discontinuation of
the study medication or results in inability to
continue or comply with study procedures
 Disease progression which requires discontinuation
of the study medication or results in the inability to
comply with study procedures
 Consent withdrawn, loss of capacity or detention
under the Mental Health Act
 Pregnancy
 In the case of an overdose
However, all efforts will be made to maintain patients in
the study where possible and to continue assessments as
intended. If treatment is stopped for longer than one week in
this study, then it will not be possible to resume it. The rea-
son for participant withdrawal will be recorded in the CRF.
Every effort will be made to attempt to continue full
protocol assessment from dropouts and/or patients who
repeatedly violate the protocol on the basis of our planned
ITT analysis. The trial may be stopped before completion
for the following reasons: (1) if the CI and/or sponsor
decide to suspend the trial pending safety review of an
emergent issue or (2) if the CI and/or sponsor decide to
stop the trial for safety, administrative or other reasons.
Discussion
Ketamine has a very favourable safety profile. One concern
with this therapy may be that ketamine can also be abused,
but we have shown that higher subanaesthetic doses of
ketamine, such as that proposed in this study, are not
rewarding [23], and recently detoxified alcoholics given
ketamine did not go on to abuse the drug [21, 24]. Also,
alcohol craving did not increase following ketamine use in
this group [24]. A clinical trial at Yale University in the
USA using ketamine for the treatment of depression in
alcoholism [25] reported the treatment to be well tolerated
with no adverse events (Petrakis IL, personal communica-
tion). Further, there has been no evidence of subsequent
drug abuse or any persisting problems when ketamine was
administered to a large sample of psychologically prepared
patients in a supportive research setting [26], and similar
absences of subsequent drug abuse have been observed in
smaller samples of depressed patients [27].
Benefits of no longer being dependent on alcohol for end
users are considerable and wide-ranging. Physical health
would improve, and risks of alcohol-related diseases such
as cirrhosis of the liver would decrease. Benefits would also
be observed in terms of end users’ mental health (depres-
sion, anxiety) and improved cognitive function, resulting in
an overall increase in quality of life. Considering the high
toll alcohol abuse has on the health system [27], benefits
would accrue in a reduction in burden on the NHS and its
workforce, in alcohol-related deaths and in other non-fatal
acute harms. Economic benefits would not only be
reflected in a reduction in burden on the NHS but also in
more frequent and regular engagement in work activities
and a reduction in crime. Importantly for end users, the
brief nature of our pharmacological intervention will be
less stigmatising than current treatments that require
taking pharmacotherapies for prolonged periods of time.
Trial status
This trial is currently recruiting patients at both study
sites.
Additional file
Additional file 1: KARE trial SPIRIT checklist detailing assessments made
in the trial. (DOC 122 kb)
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